# Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-389949 in Healthy Subjects

> **NCT02099201** · PHASE1 · COMPLETED · sponsor: **Idorsia Pharmaceuticals Ltd.** · enrollment: 65 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** ACT-389949 40 mg
- **DRUG:** ACT-389949 200 mg
- **DRUG:** ACT-389949 800 mg
- **DRUG:** ACT-389949 (Group C1 dose to be selected)
- **DRUG:** ACT-389949 (Group C2 dose to be selected)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02099201
- **Lead sponsor:** Idorsia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2018-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02099201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02099201, "Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-389949 in Healthy Subjects". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02099201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*